Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with vector biology, trial biomarkers and financing clauses is tough. Lexeo Therapeutics’ SEC disclosures are especially dense because each Form 10-K and 10-Q weaves together gene-therapy science, licensing terms with Cornell, and the cash runway needed to advance Friedreich ataxia and APOE4 Alzheimer’s trials. If you have ever asked, “How do I find Lexeo Therapeutics insider trading Form 4 transactions?” or “Where is the Lexeo Therapeutics quarterly earnings report 10-Q filing?”, you already know the challenge.
Stock Titan solves it. Our platform delivers AI-powered summaries that transform hundreds of pages into key takeaways—R&D spend, trial milestones, dilution risks. Get real-time alerts whenever a Lexeo Therapeutics 8-K material event is filed or when a scientist reports stock activity on a Form 4. The result: Lexeo Therapeutics SEC filings explained simply, without losing clinical nuance.
Use cases investors rely on every day:
- Track Lexeo Therapeutics Form 4 insider transactions real-time to gauge management confidence.
- Read a Lexeo Therapeutics annual report 10-K simplified to spot cash-burn trends and IP updates.
- Run a Lexeo Therapeutics earnings report filing analysis to compare quarter-over-quarter R&D progress.
- Review a Lexeo Therapeutics proxy statement executive compensation section in plain English.
Whether you’re understanding Lexeo Therapeutics SEC documents with AI for academic research or monitoring Lexeo Therapeutics executive stock transactions Form 4 before the next data release, Stock Titan gives you complete, continuously updated coverage—and the clarity you need to act decisively.
Lexeo Therapeutics has filed an S-3/A shelf registration statement for the resale of up to 41,630,514 shares of common stock by selling stockholders. The shares include 20,790,120 outstanding shares, 6,963,556 shares issuable from pre-funded warrants, and 13,876,838 shares from common warrants issued in a private placement on May 27, 2025.
The company is advancing genetic medicine treatments for cardiovascular diseases. Key highlights:
- LX2006 for Friedreich ataxia cardiomyopathy shows promising Phase 1/2 results with improvements in cardiac biomarkers and frataxin protein expression
- LX2020 for PKP2 arrhythmogenic cardiomyopathy is in Phase 1/2 trials
- FDA alignment achieved on accelerated approval pathway with co-primary endpoints
As an emerging growth company and smaller reporting company, Lexeo's stock trades on Nasdaq under LXEO with last quoted price of $4.19 on June 25, 2025. The company will not receive proceeds from the stock sales but will receive proceeds from any warrant exercises.
FAQ
What is the current stock price of Lexeo Therapeutics (LXEO)?
What is the market cap of Lexeo Therapeutics (LXEO)?
What is Lexeo Therapeutics Inc's core business?
Which therapeutic areas does the company focus on?
How does Lexeo advance its therapeutic pipeline?
What regulatory designations has Lexeo received?
How does the company differentiate itself in the biotech sector?
What type of gene therapy platforms does Lexeo employ?
What should investors know about Lexeo's research collaborations?
